ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 61
- Registration Number
- NCT00790660
Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00776516
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
Phase 4
Completed
- Conditions
- Benign Prostatic HyperplasiaBenign Prostatic HypertrophyOveractive Bladder
- Interventions
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 638
- Registration Number
- NCT00771394
A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia
Phase 3
Completed
- Conditions
- Functional DyspepsiaDyspepsia
- Interventions
- Drug: YM443
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 412
- Registration Number
- NCT00764374
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
Phase 1
Completed
- Conditions
- Renal Impairment
- Interventions
- Drug: YM178
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 33
- Registration Number
- NCT00750620
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 95
- Registration Number
- NCT00739453
- Locations
- 🇺🇸
University of Colorado Health Science Center, Aurora, Colorado, United States
🇺🇸Hudson-Webber Cancer Research Center, Karmanos Cancer Institute, Detroit, Michigan, United States
🇬🇧University of Oxford Department of Medical Oncology, Oxford, United Kingdom
A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.
Phase 3
Completed
- Conditions
- Liver TransplantationTransplantation ImmunologyHost vs Graft Reaction
- Interventions
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 48
- Registration Number
- NCT00720408
Drug-Drug Interaction Study of TRK-100STP
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: TRK-100STP (BERASUS LA)Drug: AST-120 (Kremezin®)
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00719758
A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2008-07-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 135
- Registration Number
- NCT00720265
A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2008-07-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 74
- Registration Number
- NCT00719745
© Copyright 2025. All Rights Reserved by MedPath